Loading...
•
Sep 30, 2020
Veru Q4 2020 Earnings Report
Reported record financial results for the fourth quarter and full year 2020.
Key Takeaways
Veru Inc. reported a strong Q4 2020, with a 35% increase in net revenues to $11.7 million and a 64% increase in gross profit to $9.6 million. The company's FC2 prescription net revenues climbed 87% to $8.7 million, driving a gross margin of 81%. The company sold its PREBOOST business for $20 million.
Net revenues increased 35% to $11.7 million.
FC2 prescription net revenues climbed 87% to $8.7 million.
Gross profit rose 64% to $9.6 million.
Gross margin increased to 81% of net revenues.
Veru
Veru
Forward Guidance
The Company expects it will have sufficient resources generated from our sexual health business and existing sources of cash to fund clinical development of all our registration clinical trials without the need for new equity financing through the end of fiscal year 2022.